308362-25-6|雷地尼唑|Ridinilazole|MFCD28963972-范德生物科技公司

雷地尼唑

NMR下载 COA and HPLC MSDS下载
names：
Ridinilazole
CAS号：
308362-25-6
MDL Number： MFCD28963972
MF(分子式)： C24H16N6 MW(分子量)： 388.42
EINECS: Reaxys Number:
Pubchem ID:16659285 Brand:BIOFOUNT

雷地尼唑(Ridinilazole,SMT19969,308362-25-6)利迪尼唑是一种不可吸收的小分子抗生素，可口服用于治疗艰难梭菌感染（CDI），与标准的万古霉素相比，在持续临床反应（SCR）率方面显示出统计学优势。

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)
YZM000108-1mg	1mg	99.51%	¥ 975.00	¥ 975.00		2-3天	- +	¥ 0.00

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	雷地尼唑(308362-25-6);利地利唑;利迪尼唑; SMT-19969；SMT 19969；SMT19969；Ridinilazole2,2'-二（吡啶-4-基）-1H，1'H-5,5'-联（苯并咪唑);（2,2'双（4-吡啶基）3H，3'H 5,5'联苯并咪唑;
英文别名	Ridinilazole(308362-25-6);SMT-19969; SMT 19969; SMT19969; Ridinilazole2,2'-di(pyridin-4-yl)-1H,1'H-5,5'-bi(benzimidazole);(2,2' bis(4-pyridyl) 3H,3'H 5,5' bibenzimidazole;
CAS号	308362-25-6
SMILES	C1(C2=CC=NC=C2)=NC3=CC(C4=CC=C5C(N=C(C6=CC=NC=C6)N5)=C4)=CC=C3N1
Inchi	InChI=1S/C24H16N6/c1-3-19-21(29-23(27-19)15-5-9-25-10-6-15)13-17(1)18-2-4-20-22(14-18)30-24(28-20)16-7-11-26-12-8-16/h1-14H,(H,27,29)(H,28,30)
InchiKey	UHQFBTAJFNVZIV-UHFFFAOYSA-N
分子式 Formula	C24H16N6
分子量 Molecular Weight	388.42
闪点 FP	352.4±28.6 °C
熔点 Melting point	No data available
沸点 Boiling point	774.9±70.0 °C at 760 mmHg
Polarizability极化度	46.4±0.5 10-24cm3
密度 Density	1.4±0.1 g/cm3
蒸汽压 Vapor Pressure	0.0±2.7 mmHg at 25°C
溶解度Solubility	生物体外In Vitro:DMSO溶解度≥ 60 mg/mL(154.47 mM)*"≥" means soluble可溶, but saturation unknown溶解度未知.
性状	固体粉末,Power
储藏条件 Storage conditions	-20°C ,3 years年 4°C 2 years年 / In solvent溶液中:-80°C 6 months月 -20°C 1 month月

雷地尼唑(Ridinilazole,SMT19969,308362-25-6)实验注意事项：
1.实验前需戴好防护眼镜，穿戴防护服和口罩，佩戴手套，避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生，必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储，并交于专业生物废气物处理公司处理，以免造成环境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

Tags:雷地尼唑试剂,雷地尼唑杂质,雷地尼唑合成,雷地尼唑中间体,雷地尼唑密度,雷地尼唑闪点,雷地尼唑熔点,雷地尼唑结构式,雷地尼唑溶解度,雷地尼唑购买,

产品说明	雷地尼唑(Ridinilazole,SMT19969,308362-25-6)是一种不可吸收的小分子抗生素,可用于治疗艰难梭菌感染(CDI)
Introduction	雷地尼唑(Ridinilazole,SMT19969,308362-25-6)is a novelantibacterialwith MICs range of 0.06.25μg/mL (MIC90=8μg/mL) againstC.difficile.
Application1	雷地尼唑(Ridinilazole,SMT19969,308362-25-6)与标准的万古霉素相比，在持续临床反应（SCR）率方面显示出统计学优势。是一种有效的新型的抗菌剂，作用于C.difficile，MIC 范围是 0.06-0.25μg/mL (MIC90=8μg/mL)
Application2
Application3

雷地尼唑(Ridinilazole,SMT19969,308362-25-6)药理学：

1、利迪尼唑正在临床试验NCT02092935中进行研究（将SMT19969与万古霉素比较用于治疗艰难梭菌相关性腹泻（CDAD））。

2、利迪尼唑是一种不可吸收的小分子抗生素，可口服用于治疗艰难梭菌感染（CDI），与标准的万古霉素相比，在持续临床反应（SCR）率方面显示出统计学优势。

警示图
危险性	warning
危险性警示	Not available
安全声明	H303吞入可能有害+H313皮肤接触可能有害+H2413吸入可能对身体有害
安全防护	P264处理后彻底清洗+P280戴防护手套/穿防护服/戴防护眼罩/戴防护面具+P305如果进入眼睛+P351用水小心冲洗几分钟+P338取出隐形眼镜（如果有）并且易于操作,继续冲洗+P337如果眼睛刺激持续+P2393获得医疗建议/护理
备注	实验过程中防止吸入、食入，做好安全防护

Vickers RJ, et al. Ridinilazole: a novel therapy for Clostridium difficile infection. Int J Antimicrob Agents. 2016 Aug;48(2):137-43.

Antimicrobial susceptibility and ribotypes of Clostridium difficile isolates from a Phase 2 clinical trial of ridinilazole (SMT19969) and vancomycin PMID 29718329; The Journal of antimicrobial chemoth

Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection PMID 26895772; The Journal of antimicrobial chemotherap

SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI PMID 25652749; The Journal of antimicrobial chemotherapy 2015;

Therapy of Clostridium difficile infection: perspectives on a changing paradigm PMID 24053182; Expert opinion on pharmacotherapy 2013 Dec; 14(17):2375-86 (Review Article) Name matches: fidaxomicin smt

雷地尼唑(Ridinilazole,SMT19969,308362-25-6)参考文献：

1.Exploring ways to improve CDI outcomes.
Galpérine T;Guery B;French Group of Fecal Microbiota Transplantation (GFTF) Med Mal Infect. 2018 Feb;48(1):10-17. doi: 10.1016/j.medmal.2017.10.009. Epub 2018 Jan 12.

Clostridium difficile is an anaerobic spore-forming Gram-positive bacillus recognized as an evolving international health problem. Metronidazole and vancomycin were - until recently - the only drugs available to treat C. difficile infection (CDI). Better knowledge of the pathophysiology and the development of new drugs completely modified the management of initial episodes and recurrences of CDI. Fidaxomicin significantly reduced recurrences compared with vancomycin. New drugs are also currently evaluated (cadazolid, surotomycin, ridinilazole, rifaximin). Gut microbiota homeostasis was clearly shown to be a key determinant in recurrences as demonstrated by the development of gut microbiota transplantation and alternative microbiota substitution. Passive immunotherapy and vaccinal approaches are also currently being evaluated. In conclusion, CDI treatment has evolved with the development of new therapeutic pathways which now need to be implemented in international guidelines.

2.Antimicrobial susceptibility and ribotypes of Clostridium difficile isolates from a Phase 2 clinical trial of ridinilazole (SMT19969) and vancomycin.
Snydman DR;McDermott LA;Thorpe CM;Chang J;Wick J;Walk ST;Vickers RJ J Antimicrob Chemother. 2018 Aug 1;73(8):2078-2084. doi: 10.1093/jac/dky135.

Objectives: ;We evaluated the antimicrobial susceptibility and ribotypes of Clostridium difficile isolates from participants in a Phase 2 study of ridinilazole, a novel targeted-spectrum agent for treatment of C. difficile infection.;Methods: ;Participants received ridinilazole (200 mg twice daily) or vancomycin (125 mg four times daily) for 10 days (ClinicalTrials.gov: ;NCT02092935;). The MICs of ridinilazole and comparators for C. difficile isolates from stool samples were determined by agar dilution. Toxin gene profiling was performed by multiplex PCR and ribotype identification by capillary electrophoresis.;Results: ;Eighty-nine isolates were recovered from 88/100 participants (one participant had two strains at baseline). The median colony count (cfu/g stool) was 1.9?×?104 (range: 2.5?×?102-7.0?×?106). Twelve participants (three received ridinilazole and nine received vancomycin) experienced recurrence, confirmed by immunoassays for free toxin in stool samples. The ribotype of eight out of nine isolates obtained at recurrence matched those of the initial isolates. All isolates, including those obtained at recurrence, were susceptible to ridinilazole within the expected range [median (range) MIC: 0.

3.New and emerging therapies for Clostridium difficile infection.
Martin J;Wilcox M Curr Opin Infect Dis. 2016 Dec;29(6):546-554.

PURPOSE OF REVIEW: ;Clostridium difficile infection has attained high prominence given its prevalence and impacts on patients and healthcare institutions. Multiple new approaches to the prevention and treatment of C. difficile infection (CDI) are undergoing clinical trials.;RECENT FINDINGS: ;Bezlotoxumab is a monoclonal antibody against toxin B that has successfully completed phase III studies, demonstrating a significant reduction in recurrent CDI when given with standard of care antibiotics. Antibiotics under development include cadazolid and ridinilazole, whereas surotomycin has had disappointing phase III results. Multiple live biotherapeutics are being developed, including freeze thawed and encapsulated versions of faecal microbiota transplantation to improve the practicality of treating patients with recurrent CDI. Alternatives to faecal microbiota transplantation, that aim to improve safety, including a microbial suspension, RBX2660, and a complex spore formulation, SER-109, have progressed to phase II studies. A nontoxigenic C. difficile strain has also shown promise to prevent recurrent CDI. In addition, three C. difficile vaccines have progressed to phase II/III clinical trials.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开